Skip to main content
Clinical Neuroscience

What a p-tau217 Blood Test Says About Your Odds of Memory Loss

Dr. Sean C. Orr, M.D. · · 6 min read

Consider a 72-year-old retired surgeon who still reads two journals a week and plays tournament bridge. His blood work comes back with an elevated p-tau217, a protein fragment that tracks Alzheimer's pathology in the brain. The lab report flags the value as abnormal and leaves it there. What he actually wants to know is a simpler question: what are my odds, and over what period of time? Until this week, most physicians answering that question were working from intuition. A Mayo Clinic paper published on November 16 in JAMA Neurology gives us numbers.

What the Mayo Clinic p-tau217 study measured

Alicia Algeciras-Schimnich, PhD, Clifford Jack Jr., MD, and colleagues at Mayo Clinic followed 2,178 cognitively unimpaired adults between the ages of 60 and 90. Of these, 1,644 came from the Mayo Clinic Study of Aging, a population-based cohort of residents of Olmsted County, Minnesota, and 534 came from the Alzheimer's Disease Neuroimaging Initiative. Every participant had a baseline plasma p-tau217 measured on the Fujirebio Lumipulse platform, APOE genotyping, and repeated cognitive assessments over time. The team then used multistate models to estimate each person's absolute risk of progressing to mild cognitive impairment, taking into account p-tau217 level, age, sex, and APOE ε4 status.

The central finding concerns absolute risk rather than relative risk. For a typical 75-year-old in the Mayo cohort, the 5-year risk of mild cognitive impairment was 7 percent at a low p-tau217 level (0.072 pg/mL, the 10th percentile) and 17 percent at a high level (0.324 pg/mL, the 90th percentile). Over 10 years, those figures rose to 15 percent and 35 percent. Moving from the 10th to the 90th percentile was associated with roughly 2 to 4 times the hazard of progression across both cohorts and across every sex and APOE subgroup.

Why age changes what a p-tau217 result means

The most clinically useful number in the paper has more to do with age than with the biomarker itself. At the same elevated p-tau217 level of 0.324 pg/mL, a 65-year-old had an estimated 5-year risk of mild cognitive impairment of 6 percent. An 85-year-old with the identical result had a 5-year risk of 37 percent. At 10 years, the gap widened from 17 percent to 66 percent.

That means the same lab value carries very different implications depending on who is holding the report. For the 65-year-old, an elevated p-tau217 is a warning with a long runway, and there is time to work on the factors that determine whether pathology in the brain ever turns into symptoms. For the 85-year-old, the same number describes a near-term probability that should shape planning conversations with family now.

The authors also found that once p-tau217 and age were accounted for, APOE ε4 carried only a modest additional association with risk. Many of my patients arrive having already paid for consumer genetic testing, and they are frightened by an APOE ε4 result. This paper supports what I tell them, which is that a measurement of what is happening in the brain right now tends to be more informative than a gene that describes a lifetime tendency.

Is a positive or negative p-tau217 result enough?

Most p-tau217 results today come back as a binary: consistent or not consistent with amyloid pathology. Dr. Algeciras-Schimnich made the point directly in the Mayo Clinic announcement, saying absolute risk is "more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology." I agree with her, and I would go further. In my practice, a positive result without a time frame tends to produce one of two reactions, panic or dismissal, and neither one leads to better care. A statement like "your 5-year risk is about 1 in 6" is something a person can reason about and act on.

Dr. Jack was quoted in Fox News coverage as saying the result "would not change your medical management at all since there's no treatment available" for people without symptoms. Here I respectfully disagree with a researcher whose work I admire. It is true that no drug is approved to treat Alzheimer's pathology in people without symptoms, and the prevention trials of anti-amyloid antibodies in this group are still under way. But the 2024 Lancet Commission on dementia estimated that nearly half of dementia cases worldwide are attributable to 14 modifiable risk factors, including hypertension, hearing loss, physical inactivity, high LDL cholesterol, diabetes, and untreated vision loss. Those factors are treatable today, and a person with a 35 percent 10-year risk has a strong reason to treat them seriously.

What this study does not tell us

This is an observational cohort, and its limits are worth stating clearly. The main cohort comes from one county in southeast Minnesota, which is not representative of the United States, and the risk estimates were built on a single assay, so results from other p-tau217 tests may not carry over number for number. Everyone in the study was 60 or older. The paper also does not show that knowing your risk changes your outcome, which would require a randomized trial. Mayo Clinic itself states that biomarker testing is not currently recommended for people without cognitive symptoms. It would be valuable to see the same model validated in more diverse populations and paired with an intervention trial that measures whether risk-factor treatment moves these numbers.

What this means for you

If you are in your 60s or 70s and considering a p-tau217 test, the decision is an individual one. It depends on your family history, your tolerance for uncertain information, and whether you would actually change anything based on the result. I have patients who want every number available and patients who would rather not know, and both are reasonable positions. What I ask is that the test be ordered by a clinician who will interpret it in the context of your age, sex, APOE status, and the rest of your health, rather than handed back as a single flag on a lab portal.

At NGP, a p-tau217 result is one input into a full precision workup that includes advanced MRI, formal cognitive testing, vascular and metabolic labs such as homocysteine, a sleep evaluation, and a hearing assessment. That is the approach behind our Intensive Brain Health Program, and the value of a risk number lies in what you do with the years it gives you. If you are curious about how midlife brain pathology develops long before symptoms, my earlier piece on Alzheimer's pathology in midlife brains covers that ground, and my recent review of bisphosphonates and dementia risk looks at one class of existing medications that has been associated with lower risk.

In the Neuroeconomy, cognition is the asset that everything else depends on, and a 10-year risk estimate is information any serious person would want about their most important asset. The Mayo study gives patients and clinicians a more honest way to talk about that risk, and the next step is to use those years well.

Hero image: illustration created with AI image tools.

This article was drafted with the assistance of AI writing tools, then reviewed, edited, and approved by Dr. Sean C. Orr, M.D., who holds full editorial responsibility for its content. This article is educational and is not a substitute for individual medical advice.

Sources:

Algeciras-Schimnich, A., Hu, M., Weigand, S. D., Therneau, T. M., Wiste, H. J., Griswold, M. E., Figdore, D. J., Bornhorst, J. A., Vemuri, P., Knopman, D. S., Graff-Radford, J., Petersen, R. C., Jack, C. R. Jr. "Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4." JAMA Neurology. Published online November 16, 2026. doi:10.1001/jamaneurol.2026.4292

Mayo Clinic News Network. "Blood biomarker helps estimate a person's future risk of cognitive impairment." November 16, 2026. news-medical.net

Rudy, M. "Alzheimer's blood marker could predict cognitive decline risks, Mayo Clinic says." Fox News. November 18, 2026. foxnews.com

Livingston, G., Huntley, J., Liu, K. Y., et al. "Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission." The Lancet. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0

Take the Next Step

This isn’t just information — it’s what we do every day.

If this article resonated with you, imagine what a full neurological evaluation and personalized treatment plan could reveal. Our programs are designed for people who are done accepting decline and ready for real answers.

Ready to talk?

A confidential consultation is the fastest way to find out if we can help.